Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abingdon HealthABDXF -0.91%49 EV-to-EBITDA is -8.85 as of Jul. 15, 2026. GuruFocus rates ABDXF with a GF Score™ of 49/100 and a GF Value™ of $0.21 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Abingdon Health ranks worse than 854700% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Abingdon Health's enterprise value is $28.38 Mil.
Abingdon Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.21 Mil. Therefore, Abingdon Health's EV-to-EBITDA for today is -8.85.
The historical rank and industry rank for Abingdon Health's EV-to-EBITDA or its related term are showing as below:
ABDXF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -37 Med: -9 Max: 125.1
Current: -8.85
During the past 8 years, the highest EV-to-EBITDA of Abingdon Health was 125.10. The lowest was -37.00. And the median was -9.00.
ABDXF's EV-to-EBITDA is ranked worse than 100% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.77
vs ABDXF: -8.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Abingdon Health (OTCPK:ABDXF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Abingdon Health's PE Ratio (TTM) for today is calculated as:
Abingdon Health's share price for today is $0.13105.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abingdon Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.011.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Abingdon Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Abingdon Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Abingdon Health's EV-to-EBITDA falls into.
Abingdon Health's current Enterprise Value is $28.38 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abingdon Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abingdon Health (ABDXF) has a EV-to-EBITDA of -8.85 as of Jul. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Abingdon Health. According to the industry distribution chart, Abingdon Health ranks #999999 out of 117 companies in the Medical Diagnostics & Research industry.
Is Abingdon Health's EV-to-EBITDA too high?
Abingdon Health's current EV-to-EBITDA is -8.85. Based on the distribution chart, Abingdon Health ranks #999999 out of 117 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #999999 out of 117 companies for EV-to-EBITDA. This places Abingdon Health in the lower half of its industry. The industry median EV-to-EBITDA is 14.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.77, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Abingdon Health. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abingdon Health's current EV-to-EBITDA is -8.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.21, compared to a current price of $0.13 — trading 37.6% below its estimated fair value. The current EV-to-EBITDA is -8.85. Abingdon Health's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current EV-to-EBITDA is -8.85 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abingdon Health (ABDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued.
The current stock price of $0.13 is trading 37.6% below its estimated GF Value™ of $0.21.
GuruFocus considers Abingdon Health to be Possible Value Trap.
Key valuation signals for ABDXF:
EV-to-EBITDA: -8.85
GF Value™: $0.21 vs. price of $0.13 (37.6% below fair value)
No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score
Get the complete analysis for ABDXF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABDXF has been successfully added to your 
